国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2009年
6期
76-77,83
,共3页
咪唑斯汀%雷公藤多甙%雷尼替丁%慢性特发性荨麻疹
咪唑斯汀%雷公籐多甙%雷尼替丁%慢性特髮性蕁痳疹
미서사정%뢰공등다대%뢰니체정%만성특발성담마진
Mizolastine%Tripterygium%Ranitidine%Chronic idiopathic urticaria
目的 观察咪唑斯汀联合雷公藤、雷尼替丁治疗慢性特发性荨麻疹的疗效及安全性.方法 随机将92例慢性特发性荨麻疹患者分为三组,治疗组(A组):服用皿治林、雷公藤多甙及雷尼替丁;对照组1(B组):服用皿治林及雷公藤多甙:对照组2(C组):服用咪唑斯汀.连服2周为1疗程,三组均连服2个疗程后观察疗效.结果 A、B、C组治愈率分别为52.38%、36%、32%;总有效率分别为90.10%、80%、72%;三组比较,差异有显著性意义(P＜0.01).结论 联合用药治疗慢性特发性荨麻疹安全有效,值得在临床中推广使用.
目的 觀察咪唑斯汀聯閤雷公籐、雷尼替丁治療慢性特髮性蕁痳疹的療效及安全性.方法 隨機將92例慢性特髮性蕁痳疹患者分為三組,治療組(A組):服用皿治林、雷公籐多甙及雷尼替丁;對照組1(B組):服用皿治林及雷公籐多甙:對照組2(C組):服用咪唑斯汀.連服2週為1療程,三組均連服2箇療程後觀察療效.結果 A、B、C組治愈率分彆為52.38%、36%、32%;總有效率分彆為90.10%、80%、72%;三組比較,差異有顯著性意義(P＜0.01).結論 聯閤用藥治療慢性特髮性蕁痳疹安全有效,值得在臨床中推廣使用.
목적 관찰미서사정연합뢰공등、뢰니체정치료만성특발성담마진적료효급안전성.방법 수궤장92례만성특발성담마진환자분위삼조,치료조(A조):복용명치림、뢰공등다대급뢰니체정;대조조1(B조):복용명치림급뢰공등다대:대조조2(C조):복용미서사정.련복2주위1료정,삼조균련복2개료정후관찰료효.결과 A、B、C조치유솔분별위52.38%、36%、32%;총유효솔분별위90.10%、80%、72%;삼조비교,차이유현저성의의(P＜0.01).결론 연합용약치료만성특발성담마진안전유효,치득재림상중추엄사용.
Objective To observe the therapeutic effect and side effect of mizolastine combined with tripterygium and ranitidine in treating chronic idiopathic urticaria. Methods 92 patients with chronic idiopathic urticaria were divided into three groups randomly. The treatment group(A) were treated with mizolastine com-bined with tripterygium and ranitidine. The control group 1 (B)were treated with mizolastine combined with tripterygium. The control group 2(C) were treated with mizolastine. The treatment lasted for 4 weeks. Result The effective rates of the three groups were 90.10%,80% and 72%, respectively.The cure rates of the three groups were 52.38%,36% and 32%, respectively. There was statistically significant difference (P< 0.01 ). Conclusion Com-bining Therapy is effective and safe in treating chronic idiopathic urticaria.
